Ligand Info
Ligand Info
Affinity DataIC50: 0.316nMAssay Description:Inhibition of GST-tagged PI4K-alpha (1 to 2044) (unknown origin) using D-myo-phosphatidylinositol as substrate preincubated for 30 mins followed by s...More data for this Ligand-Target Pair
Affinity DataIC50: 0.794nMAssay Description:Inhibition of GST-tagged PI4K-alpha (1 to 2044) (unknown origin) using D-myo-phosphatidylinositol as substrate preincubated for 30 mins followed by s...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of N-terminal FLAG-tagged human full length recombinant PI4K3alpha using D-myo-phosphatidylinositol substrate and ATP incubated for 45 min...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of GST-tagged PI4K-alpha (1 to 2044) (unknown origin) using D-myo-phosphatidylinositol as substrate preincubated for 30 mins followed by s...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of GST-tagged PI4K-alpha (1 to 2044) (unknown origin) using D-myo-phosphatidylinositol as substrate preincubated for 30 mins followed by s...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:Inhibition of GST-tagged PI4K-alpha (1 to 2044) (unknown origin) using D-myo-phosphatidylinositol as substrate preincubated for 30 mins followed by s...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:Inhibition of GST-tagged PI4K-alpha (1 to 2044) (unknown origin) using D-myo-phosphatidylinositol as substrate preincubated for 30 mins followed by s...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of N-terminal FLAG-tagged human full length recombinant PI4K3alpha using D-myo-phosphatidylinositol substrate and ATP incubated for 45 min...More data for this Ligand-Target Pair
Affinity DataIC50: 2.5nMAssay Description:Inhibition of GST-tagged PI4K-alpha (1 to 2044) (unknown origin) using D-myo-phosphatidylinositol as substrate preincubated for 30 mins followed by s...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibition of GST-tagged PI4K-alpha (1 to 2044) (unknown origin) using D-myo-phosphatidylinositol as substrate preincubated for 30 mins followed by s...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of N-terminal FLAG-tagged human full length recombinant PI4K3alpha using D-myo-phosphatidylinositol substrate and ATP incubated for 45 min...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Inhibition of GST-tagged PI4K-alpha (1 to 2044) (unknown origin) using D-myo-phosphatidylinositol as substrate preincubated for 30 mins followed by s...More data for this Ligand-Target Pair
Affinity DataIC50: 5.01nMAssay Description:Inhibition of GST-tagged PI4K-alpha (1 to 2044) (unknown origin) using D-myo-phosphatidylinositol as substrate preincubated for 30 mins followed by s...More data for this Ligand-Target Pair
Affinity DataIC50: 6.30nMAssay Description:Inhibition of N-terminal FLAG-tagged human full length recombinant PI4K3alpha using D-myo-phosphatidylinositol substrate and ATP incubated for 45 min...More data for this Ligand-Target Pair
Affinity DataIC50: 6.30nMAssay Description:Inhibition of GST-tagged PI4K-alpha (1 to 2044) (unknown origin) using D-myo-phosphatidylinositol as substrate preincubated for 30 mins followed by s...More data for this Ligand-Target Pair
Affinity DataIC50: 7.90nMAssay Description:Inhibition of N-terminal FLAG-tagged human full length recombinant PI4K3alpha using D-myo-phosphatidylinositol substrate and ATP incubated for 45 min...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibition of GST-tagged PI4K-alpha (1 to 2044) (unknown origin) using D-myo-phosphatidylinositol as substrate preincubated for 30 mins followed by s...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibition of GST-tagged PI4K-alpha (1 to 2044) (unknown origin) using D-myo-phosphatidylinositol as substrate preincubated for 30 mins followed by s...More data for this Ligand-Target Pair
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
Ligand Info
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent
TargetPhosphatidylinositol 4-kinase alpha/GTPase KRas [1-169,G12C,C51S,C80L,C118S](Human)
Frontier Medicines
US Patent
Frontier Medicines
US Patent

















































